SOLIGENIX, INC. 8-K

What Happened
Soligenix, Inc. (NASDAQ: SNGX) filed an 8-K on June 12, 2026 reporting that on June 10, 2026 it received a Nasdaq Listing Qualifications notice that the company is not in compliance with the $1.00 minimum bid price requirement (Nasdaq Rule 5550(a)(2)). The company has 180 calendar days—until December 7, 2026—to regain compliance. The filing also reports that Dr. Richard C. Straube ceased serving as the company’s Consulting Chief Medical Officer effective June 11, 2026; his responsibilities will be transitioned to Dr. Christopher Pullion, the company’s Medical Director.

Key Details

• Nasdaq notice date: June 10, 2026; compliance cure period: 180 days (deadline Dec 7, 2026).
• Regain compliance by closing bid >= $1.00 for at least 10 consecutive business days; if not, Nasdaq may start delisting and the company can appeal.
• Alternate cure: if other listing standards are met, Soligenix may get an additional 180 days by notifying Nasdaq it will effect a reverse stock split if needed.
• Dr. Straube retired as CMO effective Aug 12, 2025, began a one-year consulting agreement Aug 16, 2025 at $1,000/hour for up to 10 hours/month, and ceased his consulting CMO role June 11, 2026; he remains available on an as-needed hourly basis.

Why It Matters
For investors, the Nasdaq bid-price notice is material because failure to regain compliance could lead to delisting, which would reduce liquidity and potentially limit where shares can trade. Trading is not affected immediately; the company has defined paths to regain compliance (raising the share price or a reverse split) and may appeal any delisting determination. The change in consulting medical leadership follows the termination of the HyBryte development program and shifts medical responsibilities to the company’s Medical Director, a factual personnel change that affects who is overseeing ongoing clinical/development matters.